Brainsway Ltd. Stock Price, News & Analysis

BrainsWay (NASDAQ & TASE: BWAY) has announced its participation in the American Psychiatric Association (APA) Annual Meeting from May 17-21, 2025, in Los Angeles. The company will be featured in a master course on May 18, 2025, titled "Clinical Applications for Psychiatric Practice: Ketamine and TMS," with presentations by their Chief Medical Officer Dr. Richard Bermudes and VP of Medical Affairs Dr. Colleen Hanlon.

The company will showcase its Deep Transcranial Magnetic Stimulation (Deep TMS™) system through live demonstrations at their exhibit booth. Deep TMS is FDA-cleared for treating Major Depressive Disorder (MDD), Anxious Depression, Late-Life Depression, Obsessive-Compulsive Disorder (OCD), and Smoking Addiction.

BrainsWay, a global leader in noninvasive neurostimulation treatments for mental health disorders, has scheduled its first quarter 2025 financial results announcement for May 13, 2025, before U.S. markets open.

The company will host a conference call and webcast at 8:30 AM Eastern Time to discuss financial results and business operations. Investors can access the call through multiple channels:

• U.S. participants: 1-877-300-8521
• International callers: 1-412-317-6026
• Israel participants: 1-80-921-2373

The conference call will be available for 30-day replay on BrainsWay's investor relations website. Participants are advised to register at least 10 minutes before the call through https://investors.brainsway.com/events-and-presentations/event-calendar.

BrainsWay (NASDAQ & TASE: BWAY) reported strong financial results for Q4 and full year 2024. The company achieved record quarterly sales of $11.4 million in Q4 2024, up 27% from Q4 2023, and full-year revenue of $41 million, representing a 29% year-over-year increase.

Q4 highlights include shipping 75 Deep TMS™ systems (25% increase), maintaining a 75% gross margin, and achieving operating income of $0.4 million. Full-year 2024 showed operating income of $1.4 million, compared to a $5.0 million loss in 2023, with net income of $2.9 million.

The company secured a $20 million strategic equity financing from Valor Equity Partners and ended 2024 with $69.4 million in cash. For 2025, BrainsWay projects revenue between $49-51 million (20-24% growth) with operating income of 3-4% and Adjusted EBITDA of 11-12%.

BrainsWay (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, has announced its upcoming virtual presentation at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference.

The presentation is scheduled for March 18, 2025, at 9:20 AM EST. Investors and interested parties can access the live webcast through the Events & News – Presentations section of BrainsWay's Investor Relations website. A replay of the presentation will remain available for 30 days after the broadcast. Individual meetings with management can be arranged through Oppenheimer & Co representatives.

BrainsWay (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced it will report its fourth quarter and full year 2024 financial results on March 11, 2025, before the U.S. financial markets open.

The company will also provide operational highlights during the announcement. A conference call and webcast will be held at 8:30 AM Eastern Time to discuss these results and provide a business update. The live broadcast will be available on the company's website and will remain accessible for replay for 30 days.

BrainsWay (NASDAQ & TASE: BWAY) announced positive pilot data from an independent Stanford University study evaluating an accelerated Deep Transcranial Magnetic Stimulation (TMS) protocol for alcohol use disorder (AUD) treatment. The study, comparing 5 patients treated with BrainsWay's H7-Coil against 39 patients receiving other treatments, showed significant improvements including:

• Lower heavy drinking days (3% vs 22%)
• Reduced regular drinking days (15% vs 28%)
• Lower relapse rates (60% vs 74%)

Following the publication, the NIH awarded $1.5 million to the research team to explore Deep TMS efficacy in treating substance use addictions. The technology is not yet FDA-cleared for AUD treatment.